Overview
MEX Pharma focus is the supply of generic drugs where medicines are bioequivalent to branded alternatives in order to provide essential medicines at competativeprices to their branded equivalents. Billions are saved when hospitals use generics. Maximum percentage of generic medicines are used in USA and Western Europe.
What we supply
- Contain the same active ingredient as the innovator drug
- Are identical in strength, dosage form, and routine of administration
- Have the same use indications and efficacy
- Meet the same batch requirements for Identity, Strength, Purity and Quality.
- Are bioequivalent
The Market
The international landscape is changing for generics as it is for all pharmaceuticals.
The global generics market was valued at approximately $320 billion in 2015. Among the countries analysed by BCC Research, the generics market is worth more than $249 billion. Of the latter figure, the five major European markets (France, Germany, Italy, Spain, and the United Kingdom) account for 13%, the United States for 33%, and Japan for 6%. Generic penetration varies from country to country.
In Europe, for example, generics account for almost 22% of the German pharmaceutical market by value and for 25% in France. The Western European average share is nearly 21% compared with 19% of the US pharmaceutical market and 14% of the Japanese market. However, generic sales should register consistent growth in the five major European markets, aided by loss of patent protection on an anticipated $20 billion of marketed products.
Indian Generics
Generic drugs form 70% of the Indian pharmaceutical market.
Leading Producer
Indian pharmaceutical sector accounts for about 2.4 per cent of the global pharmaceutical industry in value terms and 10 per cent in volume terms.
High Exports
India accounts for 20 per cent of global exports in generics.
Fast Growing
The country’s pharmaceutical industry is expected to expand at a CAGR of 12.89 per cent over 2015–20.
Cost Efficient
India’s cost of production is approximately 60 per cent lower than that of the US and almost half of that of Europe.
Opportunities
Continuously increasing healthcare expenditures have pushed governments and third-party payers to seek ways to control their healthcare expenditures. This is catalysing an increasing demand for generics versus their branded counterparts.
Continuously increasing healthcare expenditures have pushed governments and third-party payers to seek ways to control their healthcare expenditures. This is catalysing an increasing demand for generics versus their branded counterparts. The continued patent cliff is also providing growing pipeline opportunities for generic firms. Similarly, healthcare reforms in the US and other developed markets coupled with strong growth in emerging market are some other important drivers for the generic medicine market.
Given a cost-savings focus, generic medicine spending growth is above the branded and overall industry average. BBC Research predicts that the global generic drugs market will reach $533 billion by 2021, driven by originator drugs facing patent expiry, pressure to control healthcare costs, the rise of bio-similar drug technologies, and high-growth market activity in emerging regions. Other demographic drivers are aging population and increasing prevalence of chronic diseases. And disease incidence increases with age.